Thymosin Alpha-1: The Oldest Immunomodulator in a New Light

Thymosin Alpha-1 (Tα1) — marketed under the synthetic name Thymalfasin (Zadaxin®) — is the first thymic peptide ever isolated. It was extracted from calf thymus in 1966 and is now one of the best-studied immunomodulatory peptides on the planet. According to a comprehensive narrative review [Dinetz & Lee 2024], more than 11,000 patients in over 30 clinical trials have received Tα1. A multicentre phase-3 sepsis trial (TESTS) published in the BMJ in January 2025 [Wu et al. 2025] has now raised the bar of evidence even further — for the first time in a rigorously designed, large-population study.

Discovery: From Crude Thymus Extract to a Defined 28-AA Peptide

In 1966, a group at the Sloan-Kettering Institute in New York described "thymosin" — an extract from calf thymus that promoted lymphocyte maturation. Over the following years, the active component was isolated: a 28-amino-acid peptide without disulfide bridges, named Thymosin Alpha-1.

First chemical synthesis succeeded in 1981. In the 1990s, Tα1 was approved as an immune therapeutic in several countries, primarily for chronic hepatitis B. Today, the synthetic version (Thymalfasin) is available in over 35 countries under the brand name Zadaxin®.

Mechanism: How Tα1 Modulates the Immune System

Unlike a classical immunostimulant, Tα1 does not push the immune system in one direction — it modulates. The peptide binds to several Toll-like receptors (TLR2, TLR3, TLR4, TLR7, TLR9) on immune cells, triggering a cascade:

• TLR3/4/9 activate IRF3 and NF-κB, leading to type-I interferons and pro-inflammatory cytokines.
• TLR2 and TLR7 activate additional pathways (NF-κB, p38MAPK, MyD88) and drive dendritic cell maturation.
• T-cell differentiation is enhanced — particularly the maturation of naïve T cells into helper and effector T cells.
• NK cells show increased cytotoxic activity under Tα1.
• Thymic output: Tα1 boosts T-cell production in the thymus — directly relevant to immunosenescence.

Clinical Applications: What Does the Evidence Say?

1. Viral Infections — Hepatitis B as the Historical Indication

Chronic hepatitis B (HBV) is the oldest and best-documented use case. A 2020 meta-analysis in BMC Gastroenterology [Peng et al. 2020] showed that Entecavir + Tα1 was superior to Entecavir monotherapy in HBV-related cirrhosis. A 2022 randomized study [Chen et al., Hepatol Int 2022] demonstrated safety and efficacy in HBV-related acute-on-chronic liver failure (ACLF).

New data keep coming: A 2026 study in Immunopharmacol Immunotoxicol [Li et al. 2026] shows that Tα1 restores immune balance in HBV-related ACLF by reducing hyperinflammation and promoting regulatory T cells.

2. COVID-19 and Post-COVID

During the pandemic, Tα1 was used extensively in China and Italy for COVID-19 patients. A 2023 meta-analysis of 8 studies [Soeroto et al., Inflammopharmacology 2023] in moderate-to-critical COVID-19 patients showed a significant 41% reduction in mortality (RR 0.59; 95% CI 0.37–0.93, p = 0.02). Mechanical ventilation needs and hospital length of stay were not significantly affected.

A 2023 study from Rome [Minutolo et al., Int Immunopharmacol 2023] also examined Tα1 in Long-COVID: the peptide restored lymphocytic immune topology that had been shifted by SARS-CoV-2 infection. A 2026 Front Immunol paper [Guo & Li 2026] further shows that Tα1 combined with checkpoint inhibitors reshapes the tumor microenvironment — a sign of the immunomodulatory potential beyond pure infectiology.

3. Sepsis — The TESTS Trial 2025 as a Turning Point

The single most important new study is the TESTS trial, published in the BMJ in January 2025 [Wu et al. 2025]. It was a multicentre, double-blind, placebo-controlled phase-3 study across 28 Chinese centres. Sepsis patients on standard care were randomized to Tα1 or placebo.

The results need to be read carefully: Tα1 improved some immunological markers but missed the primary endpoint (28-day mortality) in the overall population. A subgroup with stronger immunosuppression may have benefited — this question is being addressed in follow-up studies. A companion meta-analysis [Gu et al., Front Cell Infect Microbiol 2025] confirms that Tα1 can play a role in sepsis therapy, but only in a patient-specific manner.

4. Cancer Immunotherapy — The New Focus

An editorial in International Immunopharmacology [Mao 2023] framed the programmatic question: "Thymosin alpha 1 — Reimagine its broader applications in the immuno-oncology era". Indeed, a growing portion of Tα1 research now centers on combinations with checkpoint inhibitors:

• NSCLC (non-small cell lung cancer): Thymalfasin + checkpoint inhibitors showed improved efficacy and immunological function in a retrospective study [Wang et al., Pak J Med Sci 2026].
• Gastric cancer: A prospective trial [Xu et al., BMC Med 2026] demonstrated that neoadjuvant immunochemotherapy plus Thymalfasin is effective in locally advanced gastric cancer.
• Breast cancer: A multicentre phase-2 study [Yu et al., Cancer Immunol Immunother 2025] combined hypofractionated radiotherapy with a PD-1 inhibitor, GM-CSF, and Tα1 — promising results in metastatic solid tumors.
• Prostate cancer: Tα1 plus zoledronic acid enhanced antitumour immunity in a murine model [Wang et al., J Immunother Cancer 2023].

A 2025 study [Solmonese et al., Onco Targets Ther 2025] characterized the direct immunomodulatory effects of Tα1 on tumor cell lines and distinct immune cell subsets — the molecular basis for these combinations.

5. Immunosenescence — Reversing Thymic Involution?

A highly current 2025 review in International Journal of Molecular Sciences [Simonova et al. 2025] is dedicated to "Aging and Thymosin Alpha-1". Core message: Tα1 can counteract age-related thymic involution, boost T-cell production, and dampen chronic inflammation (inflammaging). Particularly interesting points:

• Vaccine response: Tα1 improves vaccine response in older adults — clinically relevant given the weak flu and COVID-19 vaccine reactions in this group.
• Hybrid drug "Refnot": A fusion protein of TNFα and Tα1 developed in Russia combines immunomodulation with antitumour activity at reduced toxicity.
• Antioxidant properties: Tα1 reduces oxidative stress, a driver of aging.

The authors emphasize that further clinical studies are needed to validate long-term efficacy and safety in geriatrics. But the direction is clear: Tα1 is one of the few candidates that targets the root cause of immunosenescence — declining thymic function.

6. Other Research Areas

• Severe acute pancreatitis: A 2025 meta-analysis [Tian et al., Front Immunol 2025] shows Tα1 reduces inflammation and prevents secondary infections.
• Tuberculosis: A 2025 study [Wu & Sun, Br J Hosp Med 2025] shows Tα1 + standard 2HRZE/4HR regimen improves lung function and immune parameters.
• Pulpitis: Tα1 inhibits ferroptosis in dental pulp cells [Wu et al., Int J Oral Sci 2025] — a cell-biological mechanism beyond immunomodulation.
• HIV: Tα1 induces IL-15/RA secretion in dendritic cells, restraining HIV latency in vitro [Chen et al., Virulence 2026].
• Hepatocellular carcinoma: IL-15 + Tα1 reduces senescent hepatic CD8⁺ T cells via PI3K/AKT suppression [Wu et al., J Gastroenterol Hepatol 2026].

Pharmacology and Safety

Tα1 is administered subcutaneously (typical dose: 1.6 mg to 6.4 mg per day, depending on indication). Its half-life is short (about 2 hours), but the immunomodulatory effects persist far longer. Long-acting derivative formulations such as PASylated Tα1 [Binder & Skerra, Int J Mol Sci 2020] are under development.

The safety profile is excellent. The comprehensive review [Dinetz & Lee, Altern Ther Health Med 2024] analyzed data from more than 11,000 patients across over 30 studies and concluded: Tα1 is "well-tolerated and effective". Severe adverse events are rarely documented in the literature. The most common reactions are mild injection-site reactions.

Comparison With Other Immunomodulatory Peptides

In the broader context of immunomodulatory peptide research, several distinctions are useful:

• BPC-157: Acts primarily on tissue regeneration and angiogenesis — different targets (VEGF, NO system) than Tα1.
• Thymosin Beta-4 (TB-500): The "sibling" of Tα1 from the same peptide family, but focused on wound healing, actin sequestration, and cell migration.
• Selank / Semax: Synthetic peptides with nootropic and anxiolytic effects — work via GABA / brain-derived neurotrophic factor, not primarily on TLRs.
• LL-37 (Cathelicidin): An endogenous antimicrobial peptide — different function, direct membrane attack on bacteria.

Tα1 is thus the only peptide in this lineup that primarily engages the immune regulatory system via TLR modulation — and accordingly broad is the research spectrum.

Conclusion: Mature, Relevant, Newly Discovered

Thymosin Alpha-1 is not a "new wonder peptide" — it is an old, well-studied molecule that is currently experiencing a renaissance. The reasons are manifold: a growing understanding of immunosenescence, disappointment with checkpoint-inhibitor monotherapies in many cancers, and last but not least the COVID-19 pandemic, which catapulted Tα1 into the focus of sepsis and infectious-disease research.

What remains is a sober finding: Tα1 is a safe, broadly effective immunomodulator with documented clinical experience. The interesting open questions are less about whether it works, and more about for whom, in what dose, in what combination. The TESTS trial 2025 has set the methodological bar — one that the next few years of research will build on.

Anyone considering Tα1 for longevity or performance purposes should face three realities: in the EU/Germany it is prescription-only and not centrally approved; in the US, the FDA restricted compounding access in 2023; and serious providers require medical supervision with regular immune and liver panel monitoring.